Engineered Strain Development for Enhanced Exosome Secretion
OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs
Overview
At Creative BioMart Microbe, we provide comprehensive engineered strain development services purpose-built for enhanced microbial extracellular vesicle (mEV) secretion, including bacterial outer membrane vesicles (OMVs), probiotic-derived membrane vesicles (mEVs), fungal EVs, and phage-derived vesicles. Our platform integrates synthetic biology strain engineering, secretion pathway optimization, advanced fermentation process development, and yield-enhancement validation into a single, milestone-driven workflow. Unlike mammalian exosome CDMOs that retrofit human cell protocols, we have optimized every genetic modification, promoter selection, and secretion-condition parameter for the unique membrane architecture, metabolic profile, and vesicle biogenesis mechanisms of microbial systems.
Clients receive a complete continuum from project consultation to regulatory-ready data packages. Whether you are constructing a high-yield OMV-producing E. coli strain for vaccine adjuvant applications, engineering a probiotic-derived membrane vesicle factory for gut-targeted drug delivery, or optimizing fungal vesicle secretion for cosmetic active ingredients, our team delivers quantified yield improvement, validated genetic stability, and mechanism-linked functional evidence that supports CMC, lot-release, and IND-enabling strategies. Contact us for a custom project consultation.
Figure 1. Schematic overview of the integrated engineered strain development platform for enhanced exosome secretion, spanning genetic engineering, secretion pathway optimization, fermentation process development, and yield validation.
Services
Service Workflow
Service Details
Genetic Engineering for Hypervesiculation
We apply CRISPR-Cas9 and lambda-Red recombination to systematically disrupt genes that constrain vesicle release, including tolA, lpp, msbB, and vacJ, while up-regulating phospholipid biosynthesis and membrane-stress response pathways. Each edit is selected based on the target chassis and vesicle type (OMVs, cytoplasmic membrane vesicles (CMVs) from Gram-positive bacteria, or fungal EVs) to maximize yield without compromising viability. Resulting mutants are clonally purified and sequence-verified before downstream characterization.
Surface Antigen Engineering & Display
We genetically fuse heterologous antigens, targeting ligands, or immunomodulatory peptides to outer-membrane proteins or lipoprotein anchors, enabling surface display on secreted vesicles. Immunogenicity can be tuned through lipid-A modification (msbB knockout for reduced TLR4 activation) or introduction of detoxifying mutations. Display efficiency is quantified by flow cytometry and Western blot against the surface-exposed epitope.
Payload Integration via Endogenous Loading
We integrate expression cassettes for therapeutic proteins, nucleic acids, or enzymes directly into the microbial genome or plasmid, leveraging endogenous secretion signals to load cargo into the vesicle lumen or membrane during biogenesis. Strategies include periplasmic expression with subsequent encapsulation, fusion to vesicle-sorting domains, and CRISPRi-mediated metabolic rewiring to boost cargo abundance.
Strain Characterization & Yield Validation
Every engineered clone undergoes rigorous phenotypic validation: vesicle yield is quantified by NTA and Bradford protein assay; particle size and morphology by DLS and cryo-TEM; endotoxin by LAL chromogenic assay; and genetic stability by 50-generation serial passage with whole-genome resequencing. Batch-to-batch consistency is assessed across at least three independent fermentations.
Fermentation-Ready Strain Adaptation
We optimize engineered strains for scalable production by adapting growth parameters (media composition, dissolved oxygen, pH, induction timing) from shake-flask to bench-top bioreactor (1-10 L). Process analytical technology (PAT) enables real-time monitoring of biomass and vesicle titer, ensuring the strain maintains high yield and genetic stability under production-relevant conditions.
Service Specifications & QC Standards
Engineering & Strain Capability
- CRISPR-Cas9, lambda-Red recombination, and transposon-based mutagenesis.
- Plasmid-based and chromosomal integration of expression cassettes.
- Knockout targets: tolA, tolR, lpp, msbB, mlaE, nlpI, vacJ, yebT, and custom targets.
- Overexpression targets: phospholipid biosynthesis genes (e.g., pgsA, cls, pldA), stress-response regulators (e.g., sigma-E/RpoE pathway, Cpx two-component system), and outer membrane biogenesis factors.
- Supported chassis: E. coli (K-12, BL21, Nissle 1917), Lactobacillus spp., Bacillus subtilis, Saccharomyces cerevisiae, and custom strains.
- Genetic stability verification: 50-generation serial passage with phenotype confirmation.
- Assay design aligned with MISEV2023 guidelines; GxP-compliant formats available for regulatory submissions.
Typical Data Range
- Vesicle yield improvement: 10-180x over wild-type baseline.
- Particle concentration: 1010-1012 particles/mL culture supernatant.
- Mean particle diameter: 50-250 nm (strain-dependent).
- Genetic construct stability: >95% retention over 50 generations.
- Fermentation vesicle titer: 1013-1015 particles/L at 1-10 L scale.
- Batch-to-batch yield CV: <20%.
- Endotoxin level for in vivo-grade samples: <0.5 EU/mL.
Turnaround Time
| Project Type |
Timeline |
| Strain design & construct preparation |
2-4 weeks |
| Genome engineering & clone isolation |
3-6 weeks |
| Plasmid-based strain construction |
1-3 weeks |
| Secretion pathway optimization |
4-8 weeks |
| Fermentation process development |
3-5 weeks |
| Yield enhancement validation |
2-4 weeks |
| Scale-up feasibility study (1-10 L) |
3-5 weeks |
| Integrated characterization & QC package |
2-4 weeks |
| Genetic stability assessment |
2-3 weeks |
| Complete strain development project |
12-20 weeks |
Timeline may vary based on chassis strain, modification complexity, and assay customization.
Deliverables
- Engineered strain glycerol stocks and genomic DNA.
- Experimental protocols and SOP summaries.
- Raw data files (sequencing data, NTA/DLS datasets, flow-cytometry FCS files, MS raw data).
- Processed analytical reports with statistical analysis and publication-ready charts.
- Certificate of Analysis (CoA) per batch.
- Fermentation process development report with parameter optimization matrix.
- Genetic stability assessment report.
- Optional CQA documentation package for IND-enabling studies.
Quality Control
- Batch-level instrument calibration with certified positive and negative controls.
- Inter-batch consistency assessment (yield CV <20%, particle-size CV <15%).
- MISEV2023 compliance checklist for all engineering and functional assays.
- Contaminant screening for residual antibiotics, genomic DNA, and uninduced expression.
- Endotoxin monitoring for all in vivo-grade samples.
- Optional GxP-aligned assay validation and CQA trending analysis for lot-release documentation.
Sample Requirements
| Required Information |
Optional Information |
Not Accepted |
- Strain background and genotype
- Desired modification targets (knockout/overexpression)
- Target vesicle yield improvement
- Culture volume and scale requirements
- Desired functional endpoints
- Endotoxin requirements (in vivo vs in vitro)
|
- Prior engineering history
- Target application (research, CMC, regulatory filing, publication)
- Cargo type and expression requirements
- Special strain requirements (GRAS status, auxotrophy)
- Control strain requirements (wild-type, empty vector)
- Regulatory documentation requirements (CoA, SOP, CQA package)
|
- Strains with undocumented genotype or origin
- Genetically unstable or heavily mutagenized strains
- Strains with antibiotic resistance not specified
- Contaminated or mixed cultures
- Strains preserved with fixatives or non-sterile buffers
- Strains shipped at inadequate temperature
|
Recommended Sample Quantity by Application:
| Application |
Recommended Amount |
| Genome engineering validation |
1-2 mL glycerol stock or agar stab |
| Secretion optimization screening |
≥100 mL culture supernatant |
| Fermentation process development |
≥1 L culture volume |
| Yield enhancement validation |
≥500 mL culture supernatant |
| Scale-up feasibility |
≥5 L culture volume |
| Integrated characterization |
≥200 mL culture supernatant |
| Genetic stability assessment |
Serial passage samples (n=5) |
| In vitro functional validation |
≥300 μg total vesicle protein |
| In vivo pilot studies |
≥1 mg total vesicle protein |
Storage & Shipping: Ship engineered strains as glycerol stocks on dry ice or agar stabs with cold-chain documentation. Store at –80°C upon receipt. Recommended buffer: sterile LB or defined medium with appropriate antibiotics.
Our Advantages
- Microbial EV Engineering Specialization: Deep expertise in bacterial OMVs, probiotic EVs, and fungal vesicles. Every genetic modification and secretion optimization protocol is designed for microbial membrane architecture, not adapted from mammalian templates.
- Multi-Modal Genome Engineering Toolkit: CRISPR-Cas9, lambda-Red recombination, and transposon integration operate as interchangeable modules, enabling precise knockout, knock-in, and overexpression strategies across diverse microbial chassis.
- Secretion-to-Yield Closed-Loop Optimization: Engineered strains are not released after genetic construction alone. We validate secretion efficiency, vesicle yield, cargo loading, and functional activity in an integrated optimization cycle.
- Scalable Fermentation Integration: Strain engineering and fermentation process development proceed in parallel, ensuring engineered strains are production-ready from milliliter to liter scales with PAT-enabled monitoring.
- Regulatory-Ready & Transferable: Documentation supports CMC packages and IND-enabling studies. Strain banks, SOPs, and genetic stability data are prepared for technology transfer to GMP facilities.
Applications
Therapeutic Drug Delivery System Development
Engineered mEVs deliver chemotherapeutics and nucleic-acid therapeutics to tumors and infected tissues with enhanced yields.
Vaccine Adjuvant & Antigen Delivery Engineering
High-yield OMV strains enable potent vaccine adjuvants and antigen display for bacterial and viral vaccines.
Probiotic & Functional Food-Grade Exosome Development
Food-grade probiotic strains with regulatory-cleared safety status engineered for enhanced EV secretion enable functional-food and nutraceutical applications.
Cosmetic & Skin-Targeted Delivery Systems
Engineered vesicles with enhanced yields penetrate skin barriers for anti-inflammatory and repair cosmetic benefits.
Case Study
Case Study: Engineered E. coli Nissle 1917 with 180-Fold Enhanced OMV Yield for Anti-Infective Nanotherapy
Researchers engineered probiotic E. coli Nissle 1917 through systematic knockout of vesicle retention genes to achieve record-breaking OMV production. The tolR-mlaE double-knockout strain generated 180.8-fold more vesicles than wild-type, establishing a scalable platform for therapeutic nanocarrier manufacturing. Leveraging a high-yield tolA-nlpI-msbB triple-knockout chassis optimized for exogenous protein secretion, they developed dual-functional nano-antibiotics co-delivering PslG glycoside hydrolase and tobramycin, which disrupted biofilms and demonstrated potent antibacterial efficacy against Pseudomonas aeruginosa in infection models. Additionally, antigen-displaying OMVs engineered from the same chassis served as potent nanovaccines, eliciting robust protective immunity. This work demonstrates that rational genetic engineering of secretion pathways can transform low-yield probiotic strains into industrial-scale bioreactors for precision anti-infective therapy.
Figure 3. Identification of OMVs for highly efficient secretion of foreign proteins. (Yang, et al. 2025)
FAQs
Q: What microbial chassis strains do you support for engineering?
A: We support E. coli (K-12, BL21, Nissle 1917), Lactobacillus spp., Bacillus subtilis, Saccharomyces cerevisiae, and custom strains provided by clients. Chassis selection is guided by target application, GRAS status requirements, and vesicle type (OMVs, CMVs, or fungal EVs).
Q: What types of genetic modifications can you introduce?
A: We perform knockouts (e.g., tolR, tolA, mlaE, nlpI), overexpression (phospholipid biosynthesis, stress-response regulators), chromosomal integrations, and plasmid-based expression cassettes. CRISPR-Cas9 and lambda-Red recombination are our primary editing tools.
Q: How much yield improvement can typically be achieved?
A: Yield improvements of 10-180x over wild-type baseline have been demonstrated, depending on chassis strain, modification targets, and fermentation conditions. Typical projects achieve 50-100x improvement within 12-16 weeks.
Q: Do you provide genetic stability validation?
A: Yes. All engineered strains undergo 50-generation serial passage with phenotype confirmation and whole-genome sequencing to verify construct stability. Reports include passage history, phenotype data, and sequencing alignment.
Q: Can you scale up from laboratory to pilot production?
A: Yes. We validate scale-up from shake-flask (10 mL) to bench-top bioreactor (1-10 L) with predictive modeling for pilot-scale (50-200 L). Fermentation process development is integrated with strain engineering to ensure production readiness.
Q: What is the typical turnaround for a complete strain development project?
A: Complete projects typically require 12-20 weeks, including strain design, genetic engineering, secretion optimization, fermentation development, and characterization. Standalone genome engineering can be completed in 4-9 weeks.
Q: Do you support IND-enabling documentation and CMC packages?
A: Yes. We provide comprehensive CoA, SOP summaries, method validation records, genetic stability data, batch-to-batch consistency matrices, and optional GxP-aligned CQA documentation suitable for IND submissions and regulatory filings.
Q: Can you engineer strains for specific cargo loading?
A: Yes. We can integrate cargo expression cassettes (proteins, peptides, nucleic acids) into the engineered strain genome or plasmid, enabling endogenous loading into secreted vesicles. This service integrates with our exosome engineering and drug-loading platform.
References:
- Yang, Y., et al. (2025). High-Yield Outer Membrane Vesicles Derived From Probiotics as a Nanoplatform for Precise Treatment and Prophylaxis of Pseudomonas aeruginosa Infection. Journal of Extracellular Vesicles, 14(1), e70194.
